We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+87.18%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.49B
AUM Growth
+$574M
Cap. Flow
-$341M
Cap. Flow %
-13.72%
Top 10 Hldgs %
64.37%
Holding
51
New
1
Increased
2
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$95.8M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$9.02M
3
TRVI icon
Trevi Therapeutics
TRVI
+$5.28M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$295M
2
EPZM
Epizyme, Inc
EPZM
+$67.9M
3
MRSN
Mersana Therapeutics
MRSN
+$54.7M
4
ARDX icon
Ardelyx
ARDX
+$17.4M
5
SENS icon
Senseonics Holdings Inc
SENS
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 79.28%
2 Technology 16.03%
3 Consumer Discretionary 2.25%
4 Industrials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
26
DELISTED
Genocea Biosciences, Inc.
GNCA
$16.6M 0.67%
7,225,676
– –
CSBR icon
27
Champions Oncology
CSBR
$72.4M
$16.4M 0.66%
1,713,720
– –
SBBP
28
DELISTED
Strongbridge Biopharma plc.
SBBP
$15.7M 0.63%
4,141,308
– –
BE icon
29
Bloom Energy
BE
$69.7B
$14.5M 0.58%
1,333,333
– –
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.2B
$12.4M 0.5%
992,107
– –
MRKR icon
31
Marker Therapeutics
MRKR
$18.8M
$10.3M 0.42%
500,000
– –
LUMO
32
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.69M 0.35%
526,663
– –
SYBX
33
DELISTED
Synlogic
SYBX
$8.59M 0.35%
281,961
– –
DZSI
34
DELISTED
DZS Inc. Common Stock
DZSI
$8.54M 0.34%
956,255
– –
CTIC
35
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$8.28M 0.33%
7,140,450
– –
SENS icon
36
Senseonics Holdings Inc
SENS
$272M
$6.25M 0.25%
801,192
-686,892
-46% -$7.1M
RIGL icon
37
Rigel Pharmaceuticals
RIGL
$734M
$5.93M 0.24%
324,315
– –
PHXM
38
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$5.72M 0.23%
62,500
– –
TRVN
39
DELISTED
Trevena, Inc.
TRVN
$5.72M 0.23%
6,099
– –
VRNA
40
DELISTED
Verona Pharma
VRNA
$5.71M 0.23%
1,219,674
– –
LXRX icon
41
Lexicon Pharmaceuticals
LXRX
$1.06B
$4.75M 0.19%
2,382,286
– –
TPST icon
42
Tempest Therapeutics
TPST
$14.6M
$3.11M 0.13%
9,060
– –
RGLS
43
DELISTED
Regulus Therapeutics
RGLS
$1.4M 0.06%
205,246
– –
AKTX
44
Akari Therapeutics
AKTX
$13.2M
$986K 0.04%
565
– –
TCON
45
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$680K 0.03%
17,336
– –
VIRX
46
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$342K 0.01%
37,094
– –
XFOR icon
47
X4 Pharmaceuticals
XFOR
$389M
– –
-11,111
Closed -$3.33M
SURF
48
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-3,315,149
Closed -$6.2M
EPZM
49
DELISTED
Epizyme, Inc
EPZM
– –
-4,377,518
Closed -$67.9M
RARX
50
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-6,138,797
Closed -$295M
1
2
3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
GD
Grandfield & Dodd New York $1.77B AUM 23.43% 1-Year Est. Return
DF
DNCA Finance Paris, France $1.75B AUM 38.18% 1-Year Est. Return

NEA Management Company's Q2 2020 Portfolio in Review

As of Q2 2020, NEA Management Company held 51 positions worth $2.49B, up 30% from $1.91B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

NEA Management Company withdrew a net $341M in Q2 2020, closing 5 positions and reducing 3 holdings. Its most notable exit was Ra Pharmaceuticals, Inc. Common Stock, an estimated $295M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 84% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, NEA Management Company opened a new position in Akouos Inc worth $96.7M.

  • NEA Management Company's largest Q2 2020 buy was Akouos Inc: 4,298,488 shares worth $96.7M.
  • NEA Management Company added most to AVEO Pharmaceuticals, Inc. in Q2 2020, an estimated $9.02M increase.
  • NEA Management Company's biggest Q2 2020 reduction was Mersana Therapeutics, cutting an estimated $54.7M.
  • NEA Management Company fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $295M.
  • NEA Management Company's ten largest holdings make up 64% of its $2.49B portfolio in Q2 2020.
  • NEA Management Company opened 1 new position and closed 5 in Q2 2020.
  • NEA Management Company's portfolio value rose 30% quarter-over-quarter to $2.49B.

Based on NEA Management Company's 13F filing for Q2 2020, filed 5 Aug 2020.